{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:11:05Z","timestamp":1790759465492,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cancer cachexia is a devastating metabolic syndrome characterized by systemic inflammation and massive muscle and adipose tissue wasting. Although it is responsible for approximately one-third of cancer deaths, no effective therapies are available and the underlying mechanisms have not been fully elucidated. We previously identified the bromodomain and extra-terminal domain (BET) protein BRD4 as an epigenetic regulator of muscle mass. Here we show that the pan-BET inhibitor (+)-JQ1 protects tumor-bearing mice from body weight loss and muscle and adipose tissue wasting. Remarkably, in C26-tumor-bearing mice (+)-JQ1 administration dramatically prolongs survival, without directly affecting tumor growth. By ChIP-seq and ChIP analyses, we unveil that BET proteins directly promote the muscle atrophy program during cachexia. In addition, BET proteins are required to coordinate an IL6-dependent AMPK nuclear signaling pathway converging on FoxO3 transcription factor. Overall, these findings indicate that BET proteins may represent a promising therapeutic target in the management of cancer cachexia.<\/jats:p>","DOI":"10.1038\/s41467-017-01645-7","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T16:48:37Z","timestamp":1510850917000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["Epigenetic targeting of bromodomain protein BRD4 counteracts cancer cachexia and prolongs survival"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0465-9470","authenticated-orcid":false,"given":"Marco","family":"Segatto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Fittipaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung","family":"Dae Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Fenizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpietro","family":"Zanchettin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Sefora","family":"Pierobon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0166-2773","authenticated-orcid":false,"given":"Shinji","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Sperti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Merigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagis","family":"Filippakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Costelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Sartorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-6008","authenticated-orcid":false,"given":"Giuseppina","family":"Caretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"1645_CR1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","volume":"16","author":"KC Fearon","year":"2012","unstructured":"Fearon, K. C., Glass, D. J. & Guttridge, D. C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. \n                           16, 153\u2013166 (2012).","journal-title":"Cell Metab."},{"key":"1645_CR2","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nrc3829","volume":"14","author":"JM Argil\u00e9s","year":"2014","unstructured":"Argil\u00e9s, J. M., Busquets, S., Stemmler, B. & L\u00f3pez-Soriano, F. J. Cancer cachexia: understanding the molecular basis. Nat. Rev. Cancer. \n                           14, 754\u2013762 (2014).","journal-title":"Nat. Rev. Cancer."},{"key":"1645_CR3","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ejca.2008.02.033","volume":"44","author":"KC Fearon","year":"2008","unstructured":"Fearon, K. C. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur. J. Cancer \n                           44, 1124\u20131132 (2008).","journal-title":"Eur. J. Cancer"},{"key":"1645_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1152\/physrev.00016.2008","volume":"89","author":"MJ Tisdale","year":"2009","unstructured":"Tisdale, M. J. Mechanisms of cancer cachexia. Physiol. Rev. \n                           89, 381\u2013410 (2009).","journal-title":"Physiol. Rev."},{"key":"1645_CR5","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","volume":"142","author":"X Zhou","year":"2010","unstructured":"Zhou, X. et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell \n                           142, 531\u2013543 (2010).","journal-title":"Cell"},{"key":"1645_CR6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.cell.2015.08.031","volume":"162","author":"AJ Johnston","year":"2015","unstructured":"Johnston, A. J. et al. Targeting of Fn14 prevents cancer-induced cachexia and prolongs survival. Cell \n                           162, 1365\u20131378 (2015).","journal-title":"Cell"},{"key":"1645_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1758834017698643","volume":"9","author":"Z Aversa","year":"2017","unstructured":"Aversa, Z., Costelli, P. & Muscaritoli, M. Cancer-induced muscle wasting: latest findings in prevention and treatment. Ther. Adv. Med. Oncol. \n                           9, 369\u2013382 (2017).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"1645_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/SPC.0000000000000241","volume":"10","author":"M Maddocks","year":"2016","unstructured":"Maddocks, M. et al. Practical multimodal care for cancer cachexia. Curr. Opin. Support. Palliat. Care \n                           10, 298\u2013305 (2016).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"1645_CR9","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/jcsm.12050","volume":"7","author":"F Penna","year":"2016","unstructured":"Penna, F. et al. Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting. J. Cachexia Sarcopenia Muscle \n                           7, 345\u2013354 (2016).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"1645_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","volume":"8","author":"AA Narsale","year":"2014","unstructured":"Narsale, A. A. & Carson, J. A. Role of interleukin-6 in cachexia: therapeutic implications. Curr. Opin. Support. Palliat. Care \n                           8, 321\u2013327 (2014).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"1645_CR11","first-page":"682","volume":"7","author":"ED Au","year":"2016","unstructured":"Au, E. D., Desai, A. P., Koniaris, L. G. & Zimmers, T. A. The MEK-inhibitor selumetinib attenuates tumor growth and reduces IL-6 expression but does not protect against muscle wasting in lewis lung cancer cachexia. Front. Physiol. \n                           7, 682 (2016).","journal-title":"Front. Physiol."},{"key":"1645_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00424-016-1933-3","volume":"469","author":"K Sakuma","year":"2017","unstructured":"Sakuma, K., Aoi, W. & Yamaguchi, A. Molecular mechanism of sarcopenia and cachexia: recent research advances. Pflugers. Arch. \n                           469, 573\u2013591 (2017).","journal-title":"Pflugers. Arch."},{"key":"1645_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1096\/fj.03-0610com","volume":"18","author":"SH Lecker","year":"2004","unstructured":"Lecker, S. H. et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. \n                           18, 39\u201351 (2004).","journal-title":"FASEB J."},{"key":"1645_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/SPC.0b013e3283196ac2","volume":"2","author":"D Attaix","year":"2008","unstructured":"Attaix, D., Combaret, L., B\u00e9chet, D. & Taillandier, D. Role of the ubiquitin-proteasome pathway in muscle atrophy in cachexia. Curr. Opin. Support. Palliat. Care \n                           2, 262\u2013266 (2008).","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"1645_CR15","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.ajpath.2012.12.023","volume":"182","author":"F Penna","year":"2013","unstructured":"Penna, F. et al. Autophagic degradation contributes to muscle wasting in cancer cachexia. Am. J. Pathol. \n                           182, 1367\u20131378 (2013).","journal-title":"Am. J. Pathol."},{"key":"1645_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7670","volume":"6","author":"G Milan","year":"2015","unstructured":"Milan, G. et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. Nat. Commun. \n                           6, 6670 (2015).","journal-title":"Nat. Commun."},{"key":"1645_CR17","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1101\/gad.217240.113","volume":"27","author":"V Proserpio","year":"2013","unstructured":"Proserpio, V., Fittipaldi, R., Ryall, J. G., Sartorelli, V. & Caretti, G. The methyltransferase SMYD3 mediates the recruitment of transcriptional cofactors at the myostatin and c-Met genes and regulates skeletal muscle atrophy. Genes Dev. \n                           27, 1299\u20131312 (2013).","journal-title":"Genes Dev."},{"key":"1645_CR18","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","volume":"58","author":"JS Roe","year":"2015","unstructured":"Roe, J. S., Mercan, F., Rivera, K., Pappin, D. J. & Vakoc, C. R. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol. Cell \n                           58, 1028\u20131039 (2015).","journal-title":"Mol. Cell"},{"key":"1645_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nature13229","volume":"510","author":"IA Asangani","year":"2014","unstructured":"Asangani, I. A. et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature \n                           510, 278\u2013282 (2014).","journal-title":"Nature"},{"key":"1645_CR20","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","volume":"146","author":"JE Delmore","year":"2011","unstructured":"Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell \n                           146, 904\u2013917 (2011).","journal-title":"Cell"},{"key":"1645_CR21","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nature10334","volume":"478","author":"J Zuber","year":"2011","unstructured":"Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature \n                           478, 524\u2013528 (2011).","journal-title":"Nature"},{"key":"1645_CR22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrd4286","volume":"13","author":"P Filippakopoulos","year":"2014","unstructured":"Filippakopoulos, P. & Knapp, S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. \n                           13, 337\u2013356 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1645_CR23","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/cam4.146","volume":"2","author":"HJ Stewart","year":"2013","unstructured":"Stewart, H. J., Horne, G. A., Bastow, S. & Chevassut, T. J. BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med. \n                           2, 826\u2013835 (2013).","journal-title":"Cancer Med."},{"key":"1645_CR24","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1158\/0008-5472.CAN-12-3292","volume":"73","author":"S Picaud","year":"2013","unstructured":"Picaud, S. et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res. \n                           73, 3336\u20133346 (2013).","journal-title":"Cancer Res."},{"key":"1645_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/bjc.1995.477","volume":"72","author":"S Dess\u00ec","year":"1995","unstructured":"Dess\u00ec, S. et al. Perturbations of triglycerides but not of cholesterol metabolism are prevented by anti-tumour necrosis factor treatment in rats bearing an ascites hepatoma (Yoshida AH-130). Br. J. Cancer \n                           72, 1138\u20131143 (1995).","journal-title":"Br. J. Cancer"},{"key":"1645_CR26","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1002\/ijc.27494","volume":"131","author":"J Springer","year":"2012","unstructured":"Springer, J. et al. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int. J. Cancer \n                           131, 2187\u20132196 (2012).","journal-title":"Int. J. Cancer"},{"key":"1645_CR27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.cell.2012.06.045","volume":"150","author":"MM Matzuk","year":"2012","unstructured":"Matzuk, M. M. et al. Small-molecule inhibition of BRDT for male contraception. Cell \n                           150, 673\u2013684 (2012).","journal-title":"Cell"},{"key":"1645_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/srep30340","volume":"6","author":"Z Aversa","year":"2016","unstructured":"Aversa, Z. et al. Autophagy is induced in the skeletal muscle of cachectic cancer patients. Sci. Rep. \n                           6, 30340 (2016).","journal-title":"Sci. Rep."},{"key":"1645_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2008-9-9-r137","volume":"9","author":"Y Zhang","year":"2008","unstructured":"Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. \n                           9, R137 (2008).","journal-title":"Genome Biol."},{"key":"1645_CR30","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/j.molcel.2016.12.022","volume":"65","author":"KL Cheung","year":"2017","unstructured":"Cheung, K. L. et al. Distinct roles of Brd2 and Brd4 in potentiating the transcriptional program for Th17 cell differentiation. Mol. Cell \n                           65, 1068\u20131080.e1065 (2017).","journal-title":"Mol. Cell"},{"key":"1645_CR31","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.15252\/embr.201643534","volume":"18","author":"R Fernandez-Alonso","year":"2017","unstructured":"Fernandez-Alonso, R. et al. Brd4-Brd2 isoform switching coordinates pluripotent exit and Smad2-dependent lineage specification. EMBO Rep. \n                           18, 1108\u20131122 (2017).","journal-title":"EMBO Rep."},{"key":"1645_CR32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/JES.0b013e3181f44f11","volume":"38","author":"JA Carson","year":"2010","unstructured":"Carson, J. A. & Baltgalvis, K. A. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. \n                           38, 168\u2013176 (2010).","journal-title":"Exerc. Sport Sci. Rev."},{"key":"1645_CR33","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s00280-006-0338-y","volume":"59","author":"K Fujimoto-Ouchi","year":"2007","unstructured":"Fujimoto-Ouchi, K., Onuma, E., Shirane, M., Mori, K. & Tanaka, Y. Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia models. Cancer Chemother. Pharmacol. \n                           59, 807\u2013815 (2007).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1645_CR34","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","volume":"303","author":"A Bonetto","year":"2012","unstructured":"Bonetto, A. et al. JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. \n                           303, E410\u2013E421 (2012).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1645_CR35","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.4049\/jimmunol.1202838","volume":"190","author":"AC Belkina","year":"2013","unstructured":"Belkina, A. C., Nikolajczyk, B. S. & Denis, G. V. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J. Immunol. \n                           190, 3670\u20133678 (2013).","journal-title":"J. Immunol."},{"key":"1645_CR36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature \n                           468, 1119\u20131123 (2010).","journal-title":"Nature"},{"key":"1645_CR37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/BJ20090928","volume":"425","author":"F Wang","year":"2009","unstructured":"Wang, F. et al. Brd2 disruption in mice causes severe obesity without type 2 diabetes. Biochem. J. \n                           425, 71\u201383 (2009).","journal-title":"Biochem. J."},{"key":"1645_CR38","doi-asserted-by":"publisher","first-page":"E1042","DOI":"10.1152\/ajpendo.00410.2012","volume":"304","author":"JP White","year":"2013","unstructured":"White, J. P. et al. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am. J. Physiol. Endocrinol. Metab. \n                           304, E1042\u2013E1052 (2013).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"1645_CR39","doi-asserted-by":"publisher","first-page":"e92966","DOI":"10.1371\/journal.pone.0092966","volume":"9","author":"M Tsoli","year":"2014","unstructured":"Tsoli, M. et al. Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. PLOS ONE \n                           9, e92966 (2014).","journal-title":"PLOS ONE"},{"key":"1645_CR40","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/ijc.25146","volume":"127","author":"F Penna","year":"2010","unstructured":"Penna, F. et al. Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? Int. J. Cancer \n                           127, 1706\u20131717 (2010).","journal-title":"Int. J. Cancer"},{"key":"1645_CR41","doi-asserted-by":"publisher","first-page":"30107","DOI":"10.1074\/jbc.M705325200","volume":"282","author":"EL Greer","year":"2007","unstructured":"Greer, E. L. et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J. Biol. Chem. \n                           282, 30107\u201330119 (2007).","journal-title":"J. Biol. Chem."},{"key":"1645_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.bbrc.2004.05.188","volume":"320","author":"M Kelly","year":"2004","unstructured":"Kelly, M. et al. AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem. Biophys. Res. Commun. \n                           320, 449\u2013454 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1645_CR43","doi-asserted-by":"publisher","first-page":"e24650","DOI":"10.1371\/journal.pone.0024650","volume":"6","author":"JP White","year":"2011","unstructured":"White, J. P. et al. The regulation of skeletal muscle protein turnover during the progression of cancer cachexia in the Apc(Min\/ +) mouse. PLOS ONE \n                           6, e24650 (2011).","journal-title":"PLOS ONE"},{"key":"1645_CR44","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1096\/fj.11-189977","volume":"26","author":"SA Reed","year":"2012","unstructured":"Reed, S. A., Sandesara, P. B., Senf, S. M. & Judge, A. R. Inhibition of FoxO transcriptional activity prevents muscle fiber atrophy during cachexia and induces hypertrophy. FASEB J. \n                           26, 987\u20131000 (2012).","journal-title":"FASEB J."},{"key":"1645_CR45","doi-asserted-by":"publisher","first-page":"e87776","DOI":"10.1371\/journal.pone.0087776","volume":"9","author":"EW Cornwell","year":"2014","unstructured":"Cornwell, E. W., Mirbod, A., Wu, C. L., Kandarian, S. C. & Jackman, R. W. C26 cancer-induced muscle wasting is IKK\u03b2-dependent and NF-kappaB-independent. PLoS ONE \n                           9, e87776 (2014).","journal-title":"PLoS ONE"},{"key":"1645_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-997","volume":"14","author":"SM Judge","year":"2014","unstructured":"Judge, S. M., et al. Genome-wide identification of FoxO-dependent gene networks in skeletal muscle during C26 cancer cachexia. BMC Cancer \n                           14, 1 (2014).","journal-title":"BMC Cancer"},{"key":"1645_CR47","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1158\/0008-5472.CAN-06-4585","volume":"67","author":"T Agustsson","year":"2007","unstructured":"Agustsson, T. et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. \n                           67, 5531\u20135537 (2007).","journal-title":"Cancer Res."},{"key":"1645_CR48","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1126\/science.1198973","volume":"333","author":"SK Das","year":"2011","unstructured":"Das, S. K. et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science \n                           333, 233\u2013238 (2011).","journal-title":"Science"},{"key":"1645_CR49","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6603360","volume":"95","author":"C Bing","year":"2006","unstructured":"Bing, C. et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br. J. Cancer \n                           95, 1028\u20131037 (2006).","journal-title":"Br. J. Cancer"},{"key":"1645_CR50","doi-asserted-by":"publisher","first-page":"C475","DOI":"10.1152\/ajpcell.00125.2012","volume":"303","author":"AM Sanchez","year":"2012","unstructured":"Sanchez, A. M. et al. The role of AMP-activated protein kinase in the coordination of skeletal muscle turnover and energy homeostasis. Am. J. Physiol. Cell. Physiol. \n                           303, C475\u2013C485 (2012).","journal-title":"Am. J. Physiol. Cell. Physiol."},{"key":"1645_CR51","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. \n                           12, 489\u2013495 (2011).","journal-title":"Lancet Oncol."},{"key":"1645_CR52","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nature16863","volume":"529","author":"J Settleman","year":"2016","unstructured":"Settleman, J. Cancer: bet on drug resistance. Nature \n                           529, 289\u2013290 (2016).","journal-title":"Nature"},{"key":"1645_CR53","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature14888","volume":"525","author":"CY Fong","year":"2015","unstructured":"Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature \n                           525, 538\u2013542 (2015).","journal-title":"Nature"},{"key":"1645_CR54","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature14898","volume":"525","author":"P Rathert","year":"2015","unstructured":"Rathert, P. et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature \n                           525, 543\u2013547 (2015).","journal-title":"Nature"},{"key":"1645_CR55","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature16508","volume":"529","author":"S Shu","year":"2016","unstructured":"Shu, S. et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature \n                           529, 413\u2013417 (2016).","journal-title":"Nature"},{"key":"1645_CR56","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.celrep.2016.06.091","volume":"16","author":"AM Kurimchak","year":"2016","unstructured":"Kurimchak, A. M. et al. Resistance to BET bromodomain inhibitors is mediated by kinome reprogramming in ovarian cancer. Cell Rep. \n                           16, 1273\u20131286 (2016).","journal-title":"Cell Rep."},{"key":"1645_CR57","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.celrep.2013.11.031","volume":"5","author":"A Eijkelenboom","year":"2013","unstructured":"Eijkelenboom, A., Mokry, M., Smits, L. M., Nieuwenhuis, E. E. & Burgering, B. M. FOXO3 selectively amplifies enhancer activity to establish target gene regulation. Cell Rep. \n                           5, 1664\u20131678 (2013).","journal-title":"Cell Rep."},{"key":"1645_CR58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrm3507","volume":"14","author":"A Eijkelenboom","year":"2013","unstructured":"Eijkelenboom, A. & Burgering, B. M. FOXOs: signalling integrators for homeostasis maintenance. Nat. Rev. Mol. Cell Biol. \n                           14, 83\u201397 (2013).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1645_CR59","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1038\/nsmb.2912","volume":"21","author":"T Kanno","year":"2014","unstructured":"Kanno, T. et al. BRD4 assists elongation of both coding and enhancer RNAs by interacting with acetylated histones. Nat. Struct. Mol. Biol. \n                           21, 1047\u20131057 (2014).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1645_CR60","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ccr.2014.01.028","volume":"25","author":"J Shi","year":"2014","unstructured":"Shi, J. et al. Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell \n                           25, 210\u2013225 (2014).","journal-title":"Cancer Cell"},{"key":"1645_CR61","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","volume":"23","author":"S Kir","year":"2016","unstructured":"Kir, S. et al. PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer. Cell Metab. \n                           23, 315\u2013323 (2016).","journal-title":"Cell Metab."},{"key":"1645_CR62","doi-asserted-by":"publisher","first-page":"926","DOI":"10.2337\/diabetes.52.4.926","volume":"52","author":"SL McGee","year":"2003","unstructured":"McGee, S. L. et al. Exercise increases nuclear AMPK alpha2 in human skeletal muscle. Diabetes \n                           52, 926\u2013928 (2003).","journal-title":"Diabetes"},{"key":"1645_CR63","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1091\/mbc.E10-04-0347","volume":"21","author":"N Kazgan","year":"2010","unstructured":"Kazgan, N., Williams, T., Forsberg, L. J. & Brenman, J. E. Identification of a nuclear export signal in the catalytic subunit of AMP-activated protein kinase. Mol. Biol. Cell \n                           21, 3433\u20133442 (2010).","journal-title":"Mol. Biol. Cell"},{"key":"1645_CR64","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1152\/japplphysiol.00900.2007","volume":"104","author":"DM Thomson","year":"2008","unstructured":"Thomson, D. M. et al. AMP-activated protein kinase phosphorylates transcription factors of the CREB family. J. Appl. Physiol. (1985) \n                           104, 429\u2013438 (2008).","journal-title":"J. Appl. Physiol. (1985)"},{"key":"1645_CR65","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1161\/ATVBAHA.111.237453","volume":"31","author":"Y Zhang","year":"2011","unstructured":"Zhang, Y., Qiu, J., Wang, X. & Xia, M. AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler. Thromb. Vasc. Biol. \n                           31, 2897\u20132908 (2011).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1645_CR66","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1126\/science.1191241","volume":"329","author":"D Bungard","year":"2010","unstructured":"Bungard, D. et al. Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science \n                           329, 1201\u20131205 (2010).","journal-title":"Science"},{"key":"1645_CR67","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1756-8935-6-30","volume":"6","author":"D Savic","year":"2013","unstructured":"Savic, D., Gertz, J., Jain, P., Cooper, G. M. & Myers, R. M. Mapping genome-wide transcription factor binding sites in frozen tissues. Epigenetics Chromatin \n                           6, 30 (2013).","journal-title":"Epigenetics Chromatin"},{"key":"1645_CR68","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1038\/npp.2013.284","volume":"39","author":"M Segatto","year":"2013","unstructured":"Segatto, M., et al. Simvastatin treatment highlights a new role for the isoprenoid\/cholesterol biosynthetic pathway in the modulation of emotional reactivity and cognitive performance in rats. Neuropsychopharmacology \n                           39, 841\u2013854 (2013).","journal-title":"Neuropsychopharmacology"},{"key":"1645_CR69","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","volume":"193","author":"OH Lowry","year":"1951","unstructured":"Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. \n                           193, 265\u2013275 (1951).","journal-title":"J. Biol. Chem."},{"key":"1645_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-513","volume":"5","author":"I Dimauro","year":"2012","unstructured":"Dimauro, I., Pearson, T., Caporossi, D. & Jackson, M. J. A simple protocol for the subcellular fractionation of skeletal muscle cells and tissue. BMC Res. Notes \n                           5, 513 (2012).","journal-title":"BMC Res. Notes"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01645-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01645-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T18:14:36Z","timestamp":1671732876000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-017-01645-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["1645"],"URL":"https:\/\/doi.org\/10.1038\/s41467-017-01645-7","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732150051.793539947","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]},"assertion":[{"value":"15 January 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.H. is an employee of the Novartis Institutes of Biomedical Research. The remaining authors declare that they have no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1707"}}